First International Moxifloxacin Symposium: Berlin, 1999

ISBN-13: 9783642640810 / Angielski / Miękka / 2012 / 191 str.

L. Mandell

Opis

5t The 1 International Moxifloxacin symposium took place in Berlin Germany February 18 - 20,1999. The purpose of this meeting was to introduce the medical and scientific communities to this exciting new fluoroquinolone and to define its role in the management of respiratory tract infections. The fluoroquinolones as a class are an important part of our therapeutic armamentarium and moxi floxacin is a unique addition to this class of compounds. This symposium brought together physician/scientists from around the world to present and discuss the moxifloxacin data. The information from this important meeting are presented in these proceedings and are organized under the following headings: Part I Antimicrobial chemotherapy Part II Pre-clinical microbiology Part III Pharmacology Part IV Clinical needs in the millennium Part V Round table discussion The modifications to the basic quinolone structure resulting in moxifloxacin have produced a drug with unique in vitro, and pharmacokinetic/pharmaco dynamic properties. The drug has a very broad spectrum of antimicrobial activity, is well absorbed and can be taken only once daily. Its profile makes it an excellent therapeutic option for many types of respiratory tract infections. It is hoped that our clinical and laboratory colleagues will be as excited by this data as we are and we look forward to further work with this unique and interesting compound."

Spis treści

to the Symposium.- 1 — Antimicrobial Chemotherapy.- Antimicrobial Chemotherapy — Today.- Antimicrobial Chemotherapy — Tomorrow.- PART2—Pre-clinical.- Pre-clinical Microbiology — Streptococcus Pneumoniae.- Pre-clinical Microbiology — Gram-positive Cocci.- Pre-clinical Microbiology — Atypical Organisms.- Pre-clinical Microbiology — Summary I.- Pre-clinical Microbiology — Mycobacteria.- In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria.- Pre-clinical Microbiology — Fastidious Gram-negative Bacteria.- Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — USA.- Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — Europe.- Pre-clinical Microbiology — Respiratory Tract Infections Susceptibility Survey — Japan.- Mechanisms of Fluoroquinolone Action and Resistance.- Pre-clinical Microbiology — Summary II.- 3 — Pharmacology.- Pharmacokinetics and Pharmacodynamics of Antimicrobials.- Mini-Reviews — Pharmacokinetics/Pharmacodynamics (PK/PD).- In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones.- In vitro Models of Infection — Pharmacokinetic/Pharmacodynamic Correlates.- Animal Model Experiences with Moxifloxacin.- Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials.- Pharmacology of Moxifloxacin — Absorption, Distribution, Metabolism and Excretion.- Antimicrobial Drug-Drug Interations — Focus on Fluoroquinolones.- Pharmacology — Tissue Distribution.- Fluoroquinolones Phototoxicity — Moxifloxacin in Context.- Fluoroquinolone Safety and Tolerability.- 4 — Clinical Needs in the Millenium.- Clinical Needs in the Millenium — Community Acquired Pneumonia.- Clinical Needs in the Millenium — Pneumonia — The Role of Moxifloxacin.- Clinical Needs in the Millenium — Acute Exacerbations of Chronic Bronchitis.- Clinical Needs in the Millenium — Acute Exacerbations of Chronic Bronchitis — The Role of Moxifloxacin.- Clinical Needs in the Millenium — Rhinosinusitis.- Clinical Needs in the Millenium — Rhinosinusitis — The Role of Moxifloxacin.- Discussion on Clinical Needs in the Millenium.- 5 — Round Table Discussion.- Round Table Discussion — Introduction.- Round Table Discussion — Hospital Issues.- Round Table Discussion — Community Issues.

Blurb

The proceedings of this symposium focus on the new and exciting fluoroquinolone Moxifloxacin. Physicians/scientists from around the world have contributed to this effort and the information in these proceedings has been organized as follows: Part I: Antimicrobial Chemotherapy Part II: Preclinical Microbiology Part III: Pharmacology Part IV: Clinical Needs in the Millenium Part V: Round Table Discussion It is hoped that the reader will gain an appreciation of the various basic and clinical issues pertaining to the fluoroquinolones in general and moxifloxacin in particular and the role of this agent in the management of respiratory tract infections.